Response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer

被引：3

作者：

Satoh, Hiroaki ^{[1
]}

Kagohashi, Katsunori ^{[1
]}

机构：

[1] Univ Tsukuba, Mito Med Ctr, Dept Internal Med, Div Resp Med, Miya Machi 3-2-7, Mito, Ibaraki 3100015, Japan

来源：

ANTI-CANCER DRUGS | 2022年 / 33卷 / 03期

关键词：

bevacizumab acquired resistance; erlotinib; non-small cell lung cancer; osimertinib;

D O I：

10.1097/CAD.0000000000001142

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Osimertinib is the most reliable epidermal growth factor receptor-tyrosine kinase (EGFR-TKI) and is recommended as the first-line EGFR-TKI. Therefore, developing acquired resistance to this TKI might be problematic because no appropriate treatment with TKIs has been established after acquired resistance to osimertinib. For patients with osimertinib resistance, antitumor drugs having different mechanism from that of EGFR-TKI are usually prescribed. However, these treatments do not include the effective utilization of several EGFR-TKIs for these patients. We herein report two cases of response to erlotinib and bevacizumab combination therapy after acquired resistance to osimertinib in patients with non-small cell lung cancer. Although the precise biological mechanism is unknown, this combination therapy may be an option for some patients who suffer from acquired resistance to osimertinib.

引用

页码：320 / 322

页数：3

共 6 条

[1] Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR -Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments [J].